Traduction de «Other forms systemic sclerosis » (Anglais → Français) :

1. Having regard to the impact that the failure of the institution could have, due to the nature of its business, its shareholding structure, its legal form, its risk profile, size and legal status, its interconnectedness to other institutions or to the financial system in general, the scope and the complexity of its activities, its membership of an IPS or other cooperative mutual solidarity systems as referred to in Article 113(7) of Regulation (EU) No 575/2013 and any ex ...[+++]ercise of investment services or activities as defined in point (2) of Article 4(1) of Directive 2014/65/EU, and whether its failure and subsequent winding up under normal insolvency proceedings would be likely to have a significant negative effect on financial markets, on other institutions, on funding conditions, or on the wider economy, Member States shall ensure that competent and resolution authorities determine:

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) ...[+++] what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

That, in the opinion of the House, the government should help ensure that patients suffering from Multiple sclerosis (MS), and their families and caregivers, have access to the information they need to make informed decisions in the management of their condition by ensuring that: (a) the MS monitoring system currently being developed by the Canadian Institute for Health Information contain specific and useful information, accessibl ...[+++]e directly to patients, on the risks, benefits, and other relevant aspects relative to undergoing surgical treatment for chronic cerebro-spinal venous insufficiency (CCSVI); (b) departments, agencies and programs work closely with provincial and territorial counterparts, with health professionals associations, such as the Royal College of Physicians and Surgeons, and with patient groups, such as the MS Society of Canada, on the sharing of up-to-date research-based information on the nature of CCSVI and its link to MS; and (c) the government’s two advisory boards dealing with MS ensure the patients’ concerns and views are well represented and heard at future meetings.

Question No. 397 Ms. Kirsty Duncan: With respect to initiatives and programs run by the Department of National Defence (DND) and Veterans Affairs Canada (VAC) in relation to veterans’ health and welfare: (a) what are the issues affecting (i) Canada’s traditional war veteran population, (ii) Canadian Forces (CF) veterans; (b) for each group of veterans in (a), how many cases were there per identified issue, per year, over the last five years; (c) for each group of veterans in (a), what changes have occurred in the issues over the las ...[+++]t five years; (d) for CF veterans, what key issues are anticipated following the withdrawal from Afghanistan in 2011, and for each anticipated issue, what are the (i) challenges, (ii) changes necessary to VAC, (iii) actions taken to date; (e) what recommendations, if any, have been made to improve the quality of life for veterans identified in (a) and what steps, if any, have been taken to address these recommendations; (f) what specific measures are being taken to ensure that VAC (i) responds quickly to emerging research, such as the possible link between combat and amyotrophic lateral sclerosis, and combat and dementia, (ii) implements research recommendations in a timely manner; (g) what are the categories of injuries sustained by the Canadian troops in Afghanistan; (h) what specific rehabilitation is provided for each injury category, by region; (i) what reviews of rehabilitation procedures have been undertaken, by date and region; (j) for each injury category identified in (g), what percentage of veterans are able to return to civilian work; (k) what specific measures are undertaken by region to help veterans normalize to civilian life; (l) what specific measures are used to ensure veterans returning from Afghanistan are informed of veterans' benefits; (m) what is the process for acquiring the help of a case manager; (n) what are the specific steps a veteran needs to take following a release or a medical release in order ...

The incidence of certain diseases, such as Parkinson's, AIDS, cancer, not to mention other terrible conditions such as amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease, is generating pressure on the health system in favour of the development of palliative care.

Others have more systemic problems like pain in the joints, kidney trouble, infections, sclerosis, chronic fatigue, etc.